STOCK TITAN

RedHill Biopharma Ltd. - REDIF STOCK NEWS

Welcome to our dedicated news page for RedHill Biopharma Ltd. (Ticker: REDIF), a resource for investors and traders seeking the latest updates and insights on RedHill Biopharma Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RedHill Biopharma Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RedHill Biopharma Ltd.'s position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
conferences earnings
RedHill Biopharma Ltd.

Nasdaq:REDIF

REDIF Rankings

REDIF Stock Data

34.17M
Pharmaceuticals: Major
Health Technology
Link
IL
Tel Aviv

About REDIF

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company’s subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.